Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer

We have recently reported that vatalanib, an orally active small molecule multi-tyrosine kinase inhibitor (Hess-Stumpp et al., 2005 [1]), can sensitize multidrug resistant (MDR) colon cancer cells to chemotherapy under hypoxia by inhibiting two MDR transporters ABCB1 and ABCG2 (To et al., 2015 [2])....

Descripción completa

Detalles Bibliográficos
Autores principales: To, Kenneth K.W., Poon, Daniel C., Wei, Yuming, Wang, Fang, Lin, Ge, Fu, Li-wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789311/
https://www.ncbi.nlm.nih.gov/pubmed/27014726
http://dx.doi.org/10.1016/j.dib.2016.02.064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789311/
https://www.ncbi.nlm.nih.gov/pubmed/27014726
http://dx.doi.org/10.1016/j.dib.2016.02.064

Ejemplares similares